Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis

NCT00062699 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

2200

Enrollment

INDUSTRY

Sponsor class

Conditions

End-Stage Kidney Disease

Interventions

DRUG: Zemplar (paricalcitol injection)
DRUG: Calcijex

Sponsor

Abbott